Glycyrrhizin ameliorates vascular endothelial cell senescence by inhibiting HMGB1 in HFD/STZ-induced diabetic rats and human umbilical vein endothelial cells

Eur J Pharmacol. 2022 Sep 15:931:175196. doi: 10.1016/j.ejphar.2022.175196. Epub 2022 Aug 18.

Abstract

The senescence and dysfunction of vascular endothelial cells are important features of diabetic vascular disease. High mobility group box-1(HMGB1) may be involved in vascular injury in response to high glucose. Glycyrrhizin (GL) is an HMGB1 inhibitor that significantly reduces HMGB1. However, the relationship between HMGB1 and vascular ageing in diabetes is not clear, the protective mechanism of GL against vascular injury in type 2 diabetes mellitus (T2DM) is unclear too. This study aims to examine the role of HMGB1 in vascular endothelial cell senescence and the protective effects of GL on vascular aging in high fat diet/streptozotocin (HFD/STZ) induce type 2 diabetic rats.After induction of diabetes, GL (150 mg/kg/d) was treated by gavage for 4 weeks. Results showed that compared with the Control group, the serum level of HMGB1 was increased in rats with type 2 diabetes, while the expression of HMGB1 mRNA and protein in the thoracic aorta was upregulated, with a decrease in endothelium-dependent vasodilation function and an increase in aging degree in the thoracic aorta. However, the above indicators were significantly improved after GL treatment. In HUVECs, we found that treated with HMGB1 (50, 100 and 200 ng/ml) for 48 h induced cells senescence and GL (50, 100 mg/L) significantly inhibited high-glucose-induced endothelial cell senescence, meanwhile GL (50, 100 mg/L) significantly inhibited the high-glucose-induced HMGB1 release and upregulated p53 expression. In conclusion, GL as an HMGB1 inhibitor, attenuates endothelium-dependent relaxation impairment and vascular ageing in an animal model of diabetes and high-glucose-induced endothelial cell senescence.

Keywords: Endothelial cells; Glycyrrhizin; HMGB1; Senescence; Type 2 diabetes mellitus.

MeSH terms

  • Animals
  • Cellular Senescence
  • Diabetes Mellitus, Experimental* / metabolism
  • Diabetes Mellitus, Type 2* / drug therapy
  • Diet, High-Fat
  • Endothelial Cells
  • Glucose
  • Glycyrrhizic Acid / pharmacology
  • Glycyrrhizic Acid / therapeutic use
  • HMGB1 Protein* / metabolism
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • Rats
  • Rats, Sprague-Dawley
  • Streptozocin
  • Vascular System Injuries*

Substances

  • HMGB1 Protein
  • Streptozocin
  • Glycyrrhizic Acid
  • Glucose